Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (7306)	12/16/1999 12:38:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 9719

If I'm not mistaken the model portfolio has doubled this past year--and these gains have not come from skillful short positions. Isis is a good candidate for the dead cat bounce, and seems to me anybody interested in bottomfishing a platform company should take a look at it. If nothing this is the perfect excuse for the company to get lean ahead of the 'next generation', and it's possible they simply picked a lousy target. It is too easy to declare a platform is garbage just because it fails at first, just my two cents, but I would not recommend the VD portfolio short it at $8. (I personally don't think the model portfolio should short anything, anytime, at any price). I bought a little Isis at $5 today, and expect to follow it for the years ahead...and I wish the folks at Isis every success--they'll find a target for their idea and get it to work.

To: Spekulatius who wrote (7306)	12/16/1999 1:34:00 AM
From: schadenfreude	Read Replies (1) \| Respond to of 9719

Good point about the handwriting being on the wall. Investors ignore such warnings at their peril. FWIW, Sturza has had ISIP as a short from ~$13 for some time now. So what kept you out of LGND? That POS has been a drag on my bio portfolio for years now. I'm really kicking myself for not selling my remaining shares before earnings last quarter. It was pretty obvious that sales and earnings were going to disappoint. Small, irrelevant (financially speaking, that is) drugs. Lots of debt. Massive burn. These stocks are a mess.